VILDAGLIPTIN/METFORMIN SANOSWISS õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

vildagliptin/metformin sanoswiss õhukese polümeerikattega tablett

sanoswiss uab - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 30tk; 1000mg+50mg 120tk; 1000mg+50mg 56tk; 1000mg+50mg 180tk

VILDAGLIPTIN/METFORMIN SANOSWISS õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

vildagliptin/metformin sanoswiss õhukese polümeerikattega tablett

sanoswiss uab - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 60tk; 850mg+50mg 30tk; 850mg+50mg 10tk; 850mg+50mg 56tk; 850mg+50mg 120tk; 850mg+50mg 180tk

Galvus Euroopa Liit - eesti - EMA (European Medicines Agency)

galvus

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Jalra Euroopa Liit - eesti - EMA (European Medicines Agency)

jalra

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Xiliarx Euroopa Liit - eesti - EMA (European Medicines Agency)

xiliarx

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

IPINZAN õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

ipinzan õhukese polümeerikattega tablett

zentiva k.s. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 30tk; 1000mg+50mg 10tk; 1000mg+50mg 60tk

IPINZAN õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

ipinzan õhukese polümeerikattega tablett

zentiva k.s. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 180tk; 850mg+50mg 10tk; 850mg+50mg 60tk

DALMEVIN tablett Eesti - eesti - Ravimiamet

dalmevin tablett

medochemie limited - vildagliptiin - tablett - 50mg 112tk; 50mg 180tk; 50mg 56tk; 50mg 28tk; 50mg 30tk; 50mg 90tk; 50mg 60tk; 50mg 14tk; 50mg 336tk

DALTEX õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

daltex õhukese polümeerikattega tablett

medochemie limited - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 60tk; 850mg+50mg 180tk; 850mg+50mg 30tk; 850mg+50mg 10tk

VILSPOX õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

vilspox õhukese polümeerikattega tablett

sandoz pharmaceuticals d.d. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 30tk